Video Player
Better
00:00
00:00
Better
Treatments,
More Tomorrows
Video PlayerBetter
00:00
00:00
Better
Treatments,
More Tomorrows
We are
Advancing
A late-stage pipeline of product candidates for the treatment of hard-to-treat tumors and viruses.
Innovative
Therapies
Lead program, Annamycin, planning to commence the “MIRACLE” pivotal Phase 3 clinical trial with the potential to transform the standard of care for 2nd line acute myeloid leukemia (AML).
Innovative
Therapies
Lead program, Annamycin, planning to commence the “MIRACLE” pivotal Phase 3 clinical trial with the potential to transform the standard of care for 2nd line acute myeloid leukemia (AML).
AML Clinical Day Featuring Clinicians Martin S. Tallman, MD and Michael Andreeff, MD, PhD
May 7, 2024
Priority Development Pipeline
AML Patient Journey and the Annamycin Opportunity
Latest Releases
17 Apr 2025Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" o...
01 Apr 2025Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
- Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) ...
24 Mar 2025Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
- Continued progress in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) toward first ...
Stock Information
NASDAQ: MBRX
NASDAQ: MBRX
$0.87 ▼ $-0.04 (-4.8%)
4/17/2025 4:03 PM
Corporate
Presentation
$0.87 ▼ $-0.04 (-4.8%)
4/17/2025 4:03 PM
Corporate
Presentation
